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depth in a single fraction delivered with cylindrical shaped 
flat applicators attached to a 50kV x-ray energy source 
(INTRABEAM). The flat applicator (sizes 3-6cm) was placed at 
the high-risk area within the surgical cavity, which was 
delineated by the surgeon as the area with high likelihood for 
close or positive margins. The average IORT delivery time was 
20 minutes. The single IORT fraction was the sole treatment 
for all patients with recurrent, previously treated patients 
and in one patient with parotid tumors, while the remaining 
six patients with parotid malignancies received additional 
external beam radiotherapy(EBRT) (median dose 50Gy) four 
weeks after surgery. Decision for EBRT were based on review 
of final pathology. 
 
Results: All patients underwent successful completion of 
intraoperative radiotherapy. With follow up time of 5 to 18 
months, there have been no acute side effects or 
complications related to IORT. All patients with parotid 
tumors are currently NED; in patients with recurrent tumors, 
1 of 5 has re-recurred. 
 
Conclusion: IORT with low kv x-rays appears to be an 
excellent choice for selected patients with H&N cancers, 
both primary(parotid) and recurrent disease.  
We are now in the process of initiating a prospective trial 
evaluating the use of IORT as part of primary management of 
parotid tumors at our institution.  
Detailed results will be presented. 
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Purpose or Objective: Patients treated with concurrent 
chemoradiation (CCRT) for head and neck cancer (HNC) with 
HPV(+) associated tumours have a significantly better 
prognosis compared to those with HPV(-) tumours. Similarly, 
better prognosis was associated with changes during-
treatment consisting of either a reduction in tumour volume, 
or FDG-PET SUV, or an increase in ADC. This study 
investigated a possible association between these imaging 
biomarkers and HPV status. Our hypothesis was that HPV(+) 
tumours show a stronger ADC increase and a larger volume 
and SUV decrease. 
 
Material and Methods: 13 Patients with HNC stadium III-IVA 
underwent CCRT (11 oropharynx, 1 hypopharynx and 1 oral 
cavity). HPV status was assessed using P16 staining. Patients 
received FDG-PET and MRI imaging before the start of the 
treatment and at the end of the second week. The region of 
interest consisted of the GTV and was delineated by 
dedicated radiation-oncologists. The volume and the median 
SUV and ADC were measured pretreatment and during 
treatment. Relative responses were calculated by subtracting 
the pretreatment from the during treatment value, which 
was then normalized to the pretreatment value. A new 
variable (pooled response) was computed consisting of the 
average of the relative SUV and volume decrease and ADC 
increase. A one tailed independent samples t-test compared 
the average responses between the HPV(+) and HPV(-) 
tumours. Voxel-based Pearson correlation coefficients 
between baseline and response maps were calculated for ADC 
and FDG-PET. A Fisher’s z-transformation was used to 
compare the correlation coefficients between HPV(+) and 
HPV(-) tumours. 
 
Results: 7 out of 13 tumours were HPV(+) and 6 HPV(-). 
Comparing HPV(+) to HPV(-), GTV volume decreased 42% vs 
28% (p=0.080), SUV decreased with 32% vs 5% for (p=0.074) 
and ADC increased 24% vs 7% (p=0.058) (figure 1). The total 
response was significantly higher for HPV(+) tumours (33% vs 
13%, p=0.012). Correlation coefficients between baseline and 
response maps did not differ significantly for HPV(+) and 
HPV(-) tumours (PET: z= 1.05 vs 1.08 p=0.85, ADC: z=0.47 vs 
0.51, p=0.78). 
 
Conclusion: Volume, ADC and FDG-PET individually showed a 
trend towards a higher response in the HPV(+) tumours at the 
end of the second week CCRT. The total response was 
significantly higher for HPV(+) tumours, demonstrating a 
significant association between HPV-status and imaging 
biomarkers. The similar correlation coefficients of the 
response maps indicate the spatial distribution does not 
depend on HPV status. This study emphasises the importance 
of reporting HPV status in imaging response biomarker studies 
for HNC patients. A validation of the prognostic value of 
imaging response biomarkers within HPV(+) and (-) cohorts is 
warranted. 
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Purpose or Objective: MTL005 is a novel metalloporphyrin 
that demonstrated efficacy as a radiosensitizer in oxic and 
hypoxic pre-clinical models, increasing tumour doubling times 
by 50-90% depending on radiation dose. MTL005 achieved 
higher concentrations in tumour tissue compared with normal 
tissues (6:1 ratio), and these higher levels were retained for 
up to 62 days post administration. We developed a first-in-
human phase I, open label, dose escalation, multicenter 
clinical trial to evaluate the safety and tolerability of single 
dose MTL005 in combination with radiotherapy (Part 1) and 
cisplatin chemo-radiotherapy (Part 2) in patients with locally 
advanced head & neck cancer treated with palliative and 
curative intent respectively. The results of Part 1 of the 
study are reported. 
 
Material and Methods: In Part 1 of the study MTL005 was 
administered 1 week prior to palliative radiotherapy as i.v. 
injection in 38-76 minutes. Two dose levels were explored (2 
and 4 mg/kg). Patients were immobilised in a thermoplastic 
mask and a contrast enhanced CT scan was used to define the 
PTV and the organs at risk. Radiotherapy was delivered with 
IMRT with a total dose of 50Gy to the PTV in 25 consecutive 
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fractions for 5 days a week. Toxicity was recorded using the 
CTCAE v4.0 to define a Dose Limiting Toxicity (DLT) and a 
Maximum Tolerated Dose (MTD) of MTL005. 
 
Results: A total of 8 patients, 7 males (88%) and 1 female 
(12%), were enrolled, 4 in each of the 2 dose level cohorts. 
Six patients, all male with median age of 65 (54-77), were 
dosed with MTL005 successfully, 3 in each cohort. Dosing 
failures were due to an unexpected severe pain reaction (1 
patient) and a technical problem with the infusion line (1 
patient). In the 6 evaluable patients the following adverse 
events were recorded. Grade ≤2 oral mucositis and dysphagia 
were recorded in 3 (50%) and 4 (67%) patients respectively. 
Grade 1 pain in site of MTL005 injection was assessed in 1 
(17%) patient. Grade ≤2 other toxicities (anaemia, dysgeusia) 
occurred in 3 (50%) patients. Grade 3 (dyspnoea, 
pneumonitis, oral haemorrhage, back pain, hyperuricemia) 
and Grade 4 toxicity (sepsis) were recorded in 4 (67%) and 1 
(17%) cases respectively requiring hospitalisation and being 
considered as Serious Adverse Events (SAE). None of the SAE 
was assessed as directly related to MTL005 so DLT/MTD was 
not defined. 
 
Conclusion: We completed Part 1 of the study and MTL005 
DLT/MTD was not defined. Part 2 has been commenced with 
a MTL005 starting dose of 4mg/kg and is currently ongoing. 
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Purpose or Objective: To assess the prognostic role of 18F -
FDG PET/CT based response evaluation after primary 
concomitant radio-chemotherapy (RCT) for loco regionally 
advanced Head and Neck squamous cell carcinoma (HNSCC). 
 
Material and Methods: 150 patients were included in this 
retrospective study. Mean age was 59 years (107 males and 
43 females). The sites of HNSCC were oropharynx (53%), 
nasopharynx (14%), oral cavity (10%), hypopharynx (7%), 
larynx (7%), salivary glands (5%) and paranasal sinuses (4%). 
All patients underwent 18F-FDG PET/CT between 2006 and 
2013 to assess treatment response; 62% of patients also had a 
pre-therapy 18F -FDG PET/CT scan. 18F -FDG PET/CT was 
performed from 6 to 36 weeks (median 21 weeks) after the 
end of RCT. Patients were divided in three groups: 18F -FDG 
PET/CT performed from 6 to 14 weeks after the end of RCT 
(group I: 30 patients), from 15 to 23 weeks (group II: 89 
patients) and from 24 to 36 weeks (group III: 31 patients). 
18F -FDG PET/CT scans were performed according to 
standard procedure, then they were visually analysed by 2 
expert physicians and categorized as negative (“score 1”), 
doubt negative (“score 2”), doubt positive (“score 3”) and 
positive (“score 4”). Patients were followed-up, based on 
clinic and radiological and/or histological findings. Median 
follow up was 38 months (range, 12-60 months). At the end 
of the follow-up 18F-FDG PET/CT were classified as true 
positive (TP), true negative (TN), false positive (FP) and false 
negative (FN). 
 
Results: Group I showed “score 1” in 14 patients, “score 4” 
in 11 patients and therefore 18F-FDG PET/CT sensitivity was 
69%, specificity 83%, VPP 82%, VPN 72%, and accuracy 0.76. 
This group showed 5 doubt scans (16%) as “score 2” that were 
find out to be 2 negatives and 3 positives. No “score 3” was 
observed in this group. Group II showed “score 1” in 55 
patients, “score 4” in 27 patients and therefore 18F-FDG 
PET/CT sensitivity was 87%, specificity 98%, VPP 96%, VPN 
93%, and accuracy 0.94. This group showed 7 (8%) doubt 
scans: 3 scans (3.5%) as “score 2” that in follow-up were 1 
negative and 2 positives and 4 scans (4.5%) as “score 3” that 
were found out to be 2 negatives and 2 positives. Group III 
showed “score 1” in 24 patients and “score 4” in 6 patients 
and therefore 18F-FDG PET/CT sensitivity was 86%, 
specificity 100%, VPP 100%, VPN 96%, and accuracy 0.97. This 
group showed only 1 doubt scan (3%) as “score 2” that was 
find out to be negative. 
 
Conclusion: According to our data, PET/CT with 18F-FDG 
showed an excellent prognostic value of treatment response 
to primary concomitant RCT if performed at least 14 weeks 
after the end of RCT. We also observed that the numbers of 
“doubt scans” significantly decrease 14 weeks after the end 
of RCT. 
 
EP-1050  
Volume definition in radiotherapy planning for thyroid 
cancer: a retrospective observational study 
E. Farina
1Radiation Oncology Center- Sant'Orsola-Malpighi Hospital- 
University of Bologna, Department of Experimental- 
Diagnostic and Specialty Medicine- DIMES, Bologna, Italy 
1, S. Cammelli1, A. Arcelli1, G. Zanirato1, R. Frakulli1, 
L. Tagliaferri2, A.G. Morganti1, S. Fanti3, F. Monari1 
2Policlinico Universitario “A. Gemelli”- Università Cattolica 
del Sacro Cuore, Department of Radiotherapy, Roma, Italy 
3Nuclear Medicine Unit- Sant'Orsola-Malpighi Hospital- 
University of Bologna, Department of Experimental- 
Diagnostic and Specialty Medicine- DIMES, Bologna, Italy 
 
Purpose or Objective: The role of post-operative external 
beam radiotherapy (EBRT) in differentiated thyroid 
carcinomas is still discussed considering the low clinical 
aggressiveness and the possibility to perform a radioiodine 
ablation (RAI). However, there are dedifferentiated tumors 
that, over time, lose their capacity to capture Iodine. The 
aim of this study is to evaluate the utility of 18F-FDG PET/CT 
in volumes defining and the clinical response rate after EBRT 
in these patients. 
 
Material and Methods: Patients with locally recurrent thyroid 
cancer, treated with radical EBRT from October 2011 to 
March 2015 after total thyroidectomy and RAI, were included 
in the study. When EBRT was planned, thyroglobulin (HTG) 
was detectable and there was negative post-RAI whole body 
scintigraphy (WBS) and no surgical indications. All patients 
underwent a pre-treatment 18F-FDG PET/CT that resulted 
positive: 3 in loggia, 3 in loggia and lymph nodes, 9 in lymph 
nodes, 1 in lymph nodes and in lung. EBRT was delivered with 
IMRT-SIB technique: a dose of 66 Gy (2.2 Gy/fr) to increased 
FDG-uptake areas, 60 Gy (2 Gy/fr) to ipsilateral lymph nodes 
and 54 Gy (1.8 Gy/fr) to contralateral ones, in 30 fractions, 1 
fr/die. A revaluation 18F-FDG PET/CT and HTG dosage during 
the follow-up (range: 5-43 months) was performed. Acute 
and late toxicity were assessed with CTCAE v. 4.03 and 
EORTC-RTOG scales respectively, the metabolic, clinical and 
instrumental response with PERCIST and RECIST criteria. 
Local control (LC) and overall survival (OS) were analysed 
with Kaplan-Meier method. 
 
Results: Sixteen patients were treated and analyzed 
consecutively [M / F: 8/8; median age: 71 years; range: 36-
81; histology: 15 papillary carcinomas and 1 follicular 
carcinoma; UICC stage: III-IV]. Post-EBRT 18F-FDG PET/CT 
showed CR in 7 (43.8%), PR in 5 (31.2%), SD in 4 (25.0%) 
patients and unknown lung metastases in 2 patients (12.5%). 
HTG decreased in agreement with PET/CT results. 4 patients 
(25.0%) had G3 skin acute toxicity and no one showed G4 late 
toxicity. LC and OS rates were 100% at last follow-up (median 
F-UP: 12.3 months). 
 
